PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arcrLink to Publisher's site
 
Alcohol Res. 2012; 34(4): 506–515.
PMCID: PMC3860393

Resilience to Meet the Challenge of Addiction

Psychobiology and Clinical Considerations
Tanja N. Alim, M.D.
Tanja N. Alim, M.D.,is an assistant professor at the Department of Psychiatry and Behavioral Sciences, Howard University, Washington, DC.
William B. Lawson, M.D.
William B. Lawson, M.D.,is a professor and chair of the Department of Psychiatry at the Department of Psychiatry and Behavioral Sciences, Howard University, Washington, DC.
Adriana Feder, M.D.
Adriana Feder, M.D.,is an assistant professor at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.
Brian M. Iacoviello, Ph.D.
Brian M. Iacoviello, Ph.D.,is a postdoctoral fellow at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.
Shireen Saxena, M.S.
Shireen Saxena, M.S.,Research associate at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.
Christopher R. Bailey
Christopher R. Bailey,Research associate at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.
Allison M. Greene, M.S.
Allison M. Greene, M.S.,Research associate at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.

Abstract

Acute and chronic stress–related mechanisms play an important role in the development of addiction and its chronic, relapsing nature. Multisystem adaptations in brain, body, behavioral, and social function may contribute to a dysregulated physiological state that is maintained beyond the homeostatic range. In addition, chronic abuse of substances leads to an altered set point across multiple systems. Resilience can be defined as the absence of psychopathology despite exposure to high stress and reflects a person’s ability to cope successfully in the face of adversity, demonstrating adaptive psychological and physiological stress responses. The study of resilience can be approached by examining interindividual stress responsibility at multiple phenotypic levels, ranging from psychological differences in the way people cope with stress to differences in neurochemical or neural circuitry function. The ultimate goal of such research is the development of strategies and interventions to enhance resilience and coping in the face of stress and prevent the onset of addiction problems or relapse.

Keywords: Addiction, substance abuse, stress, acute stress reaction, chronic stress reaction, biological adaptation to stress, psychological response to stress, physiological response to stress, resilience, relapse, coping skills, psychobiology

Evidence from different disciplines suggests that acute and chronic stress–related mechanisms play an important role in both the development and the chronic, relapsing nature of addiction (Baumeister 2003; Baumeister et al. 1994; Brady and Sinha 2005). Stress is defined as the physiological and psychological process resulting from a challenge to homeostasis by any real or perceived demand on the body (Lazarus and Fokman 1984; McEwen 2000; Selye 1976). Stress often induces multisystem adaptations that occur in the brain and body and affect behavioral and social function. The resulting dynamic condition is a dysregulated physiological state maintained beyond the homeostatic range. This definition and conceptualization of stress was further developed to explain the chronic abuse of substances and comfort foods and has been studied in the context of behavioral addiction (i.e., pathological gambling) (Dallman et al. 2005; Koob and Le Moal 1997; Koob 2003).

Persistent challenges to an organism through chronic substance use may ultimately lead to an altered set point across multiple systems. This hypothesis is consistent with evidence that suggests adaptations in brain reward and stress circuits, and local physiology (e.g., energy balance) can contribute to addictive processes. Cravings or urges, decreases in self-control, and a compulsive engagement in unhealthy behaviors each characterize patients with addiction (Dallman et al. 2005; Kalivas and Volkow 2005; Koob et al. 2004; Sinha 2001). Alternatively, a person’s ability to successfully cope with high stress is reflected in adaptive physiological and psychological responses (Charney 2004; MacQueen et al. 2003).

Resilience, defined as the absence of psychopathology despite exposure to high stress, can be studied by examining interindividual differences in stress responsivity across an organism’s various types (i.e., at multiple phenotypic levels). Responsivity ranges from psychological differences in the way individuals cope with stress to differences in neurochemical or neural circuitry function (Cicchetti and Blender 2006). Variability within the genetic makeup and quality of early-life experience, as well as interactions between the two, are known to contribute to differences in stress resilience (Enoch 2010; Heim and Nemeroff 2001). Genetic influences can stem from gene–environment interactions, changes in gene expression influenced by the environment (i.e., epigenetic changes), or variation within the actual genetic code. Some examples of genetic influences on resilience include variability in the genes involved in the body’s stress response (i.e., those controlling the hypothalamic–pituitary–adrenal [HPA] axis). These include those coding for the corticotropin-releasing factor (CRF) type 1 receptor or the glucocorticoid receptor (GR) (which cortisol can activate) as well as the serotonin transporter cathecol-O-methyltransferase (COMT), neuropeptide Y (NPY), and brain-derived neurotrophic factor (BDNF) genes (Feder et al. 2009) Genetic variation in the gene encoding the CRH1 receptor was found to moderate the impact of stress, for example, among adolescents engaging in heavy drinking (Blomeyer et al. 2008; Schmid et al. 2010). This gene-by-environment interaction predicted the initiation of drinking in adolescence as well as progression to heavy drinking by young adulthood (Schmid et al. 2010). The following sections highlight resilient responses to stress in studies in which stress was identified as an important factor contributing to the neurobiology of alcohol dependence.

Psychosocial Factors Associated With Resilience

Early studies of children exposed to adversity (Masten 2001; Masten and Coatsworth 1998; Rutter 1985) as well as more recent studies in resilient adults (Ahmad et al. 2010; Alim et al. 2008; Bonanno 2004) have identified a range of psychosocial factors associated with successful adaptation to stressful or traumatic events. For example, the ability to simultaneously experience both positive and negative emotions when confronted with a high-stress situation increases flexibility of thinking and problem solving and can buffer individuals from developing stress-induced adverse consequences (Fredrickson 2001; Ong et al. 2006). Likewise, optimism has been associated with resilience to stress-related disorders, including alcohol use disorders (Ahmad et al. 2010; Alim et al. 2008).

Unlike personality characteristics associated with increased risk for substance use disorders (e.g., impulsivity, novelty seeking, and negative emotionality), positive emotionality, the tendency to experience positive mood frequently, was found to be associated with resilience to substance use in a large longitudinal study of public school students followed from late childhood through midadolescence (Wills et al. 2001). In this study, positive emotionality was found to buffer the effects of parent–child conflict and of parental and peer substance use on adolescent substance use. The ability to focus attention on performing and completing tasks was identified as a protective factor against substance use (Wills et al. 2001). The ability to focus attention might relate to the capacity to cope by planning and problem solving in times of stress, both types of coping styles characteristic of resilient individuals (Southwick et al. 2005).

Veenstra and colleagues (2007) examined the impact of coping style on alcohol use in response to stressful life events in a sample of 1,608 men and 1,645 women drawn randomly from the Dutch Lifestyle and Health Study (Veenstra et al 2007). Individuals who scored high on emotion coping, a coping style focused on feelings and emotional content to cope with stress, used more alcohol when experiencing a negative life event, compared with those who scored low on emotion coping. Alcohol use in times of stress did not vary by cognitive or by action coping, but the study found that cognitive coping and having more social contacts was linked to lower alcohol use in general. Another study of more than 1,300 adult drinkers in the general population from a New York county found stress-induced drinking in a subset of men (but not women) who scored high on avoidance coping and on positive expectancy from alcohol (Cooper et al. 1992). Men with low-avoidance coping and low expectancy from alcohol, on the other hand, actually showed a negative relationship between stressful life events and alcohol use. Of note, low avoidance coping has been linked to stress resilience in general, in several other studies (Alim et al. 2008; Carver et al. 1997).

Neurochemistry of Resilience

“Allostasis” refers to the dynamic process through which the body adapts to daily stressors and maintains homeostasis (Sterling and Eyer 1988). Sudden stressful events trigger the release of the “flight-or-fight” hormones (i.e., catecholamines) and other stress hormones in the brain, preparing the organism to cope with stress and avert harm. This process is mediated by a stress circuit (see figure 1), which is consistently implicated in stress-related disorders such as mood and anxiety disorders and addictive disorders. Interindividual variability in stress resilience results from differences in the coordinated stress response. This response comprises the function and interactions of numerous hormones, neurotransmitters, and neuropeptides, some of which are discussed below.

Figure 1
Norepinephrine (NE) and dopamine (DA) are the principle chemical messengers employed in central and peripheral sympathetic synapses, and the human NE transporter rapidly clears NE and DA from the synaptic cleft via efficient transport system-attenuating ...

HPA Axis

The HPA axis is a system regulated by a complex negative-feedback system. CRF, released by the hypothalamus in response to stress, triggers the release of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. This process leads to the synthesis and release of cortisol by the adrenal cortex. Cortisol secretion acutely facilitates cognitive, metabolic, immunologic, and behavioral adaptations to stress. It also results, however, in “allostatic overload” when stress becomes chronic or overwhelming (McEwen 2003). Resilience is maintained when the stress response is both activated and terminated efficiently. The adaptive responses of the HPA axis are thought to involve an optimal balance of the cortisol-binding receptors GR and mineralocorticoid receptor (de Kloet et al. 2005, 2007).

Studies showing lower plasma levels of ACTH but not cortisol in men with a family history of alcoholism (Dai et al. 2007; Gianoulakis et al. 2005) suggest that HPA axis dysfunction might predate the onset of alcoholism. Long-term alcohol abuse is associated with increased extrahypothalamic CRF signaling and dampened HPA axis responsivity (Richardson et al. 2008). Increases in extrahypothalamic CRF contribute to negative emotional states during abstinence, increasing risk for relapse (Koob and Le Moal 2008). In a recent study, researchers asked alcoholics who had been abstinent for 1 month to imagine a relaxing situation of their choice while listening to a previously recorded audiotape of this situation. A greater cortisol-to-corticotropin ratio (i.e., higher adrenal sensitivity) during this relaxed state was found to predict a shorter time to alcohol relapse, thus suggesting that new treatments aimed a decreasing adrenal sensitivity could reduce relapse rates (Sinha et al. 2011).

Norepinephrine

During the acute stress response, the hormone norepinephrine (NE) is released through direct projections from the brain site where NE is synthesized (i.e., locus coeruleus) and other brain stem nuclei (i.e., structures that act as transit points for brain signals) into the amygdala, hippocampus, nucleus accumbens, prefrontal cortex (PFC), and other brain areas mediating emotional responses. Several studies have linked abnormal regulation of brain NE systems to stress disorders (Krystal and Neumeister 2009; O’Donnell et al. 2004). As drug dependence develops, levels of the neurotransmitter dopamine decrease and the NE stress system in the brain is activated, contributing to “stress-like states” and increased vulnerability to stressors during periods of abstinence (Koob and Le Moal 2008). In combination with CRF, NE also might contribute to the consolidation of emotional memories associated with drug use in the amygdala (Koob et al. 2009).

Stress resilience may be enhanced through the regulation of NE system responsiveness, which is mediated through effects on the NE transporter on catecholamine receptors (i.e., α2 adrenoreceptors), as well as interactions between the NE and other neurobiologic systems, such as the dopamine and serotonin systems (Krystal and Neumeister 2009). For example, animal studies have shown that PFC NE nerve cell projections (i.e., axons) have a latent capacity to enhance synthesis and recovery of transmitter, which might underlie the capacity to adapt to stress (Miner et al. 2006). This mechanism deserves further study in humans with positron emission tomography (PET), which uses positron-emitting radiotracers to show where and how compounds act in the brain (Ding et al. 2005). Other targets include the α2a and α2c receptors, which have complementary roles in the regulation of stress responses (Small et al. 2000). Yohimbine, a drug that blocks the α2 receptors (i.e., a receptor antagonist), increases alcohol self-administration and induces reinstatement of alcohol seeking (Le et al. 2005; Marinelli et al. 2007). The recent finding that an α2c receptor polymorphism (Del322–325) reduces feedback inhibition of sympathetic NE release (Neumeister et al. 2005) as well as evidence from studies in mice bred to have an inactivated α2c receptor (i.e., knockout mice) (Sallinen et al. 1999), suggest that interventions targeting this receptor might modulate stress and anxiety responses.

Serotonin

The serotonin (5-HT) system, which consists primarily of neurons from the dorsal raphe nuclei that project widely throughout the brain (including the amygdala, ventral striatum, and PFC), is involved in the regulation of stress and anxiety. Serotonin has an important role in promoting neuroplasticity in the central nervous system, both during development and in adulthood. Serotonin also regulates the neurochemical effects of drugs of abuse, including alcohol, and is involved in modulating impulsivity, known to increase risk for alcohol and drug abuse (Kirby et al. 2011). The 5-HT system is itself modulated by drugs of abuse. For example, alcohol administration elevates 5-HT levels in the nucleus accumbens, ventral tegmental area (VTA), amygdala, and hippocampus, an effect that is more pronounced in alcohol-preferring rats. Reduced activity of the 5-HT system might contribute to depression during withdrawal and increase vulnerability to relapse (Kirby et al. 2011). In studies of macaques, differential function of the 5-HT system in interaction with early life stress was found to affect alcohol consumption: peer-reared female macaques with a specific variant (i.e., the l/s genotype) of the serotonin transporter polymorphism showed higher levels of ethanol preference and increased consumption over time (Barr et al. 2004).

The 5-HT system is extremely complex, including at least 14 receptor subtypes. Of these receptors, the 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptors are well understood through research on anxiety regulation in both animals and humans (Krystal and Neumeister 2009). The 5-HT1A receptor is thought to counteract the deleterious effects of 5-HT2A receptor activation (i.e., the disruption of brain cell creation), mediated by increased release of the neurotransmitter glutamate and direct glucocorticoid effects (Hoebel et al 2007). Restrained function of another 5-HT receptor, 5HT1B, might be central to resilient stress responses by enhancing synaptic availability of 5-HT in the amygdala and other cortical regions as well as promoting dopamine release in the ventral striatum (Clark and Neumaier 2001; Krystal and Neumeister 2009; Sari 2004) (see figure 2).

Figure 2
Alterations in serotonin 1B receptor (5HT1BR) function might contribute to alcohol dependence by influencing not only serotonin (5HT) input to the ventral striatum via the receptors’ role as 5HT terminal autoreceptors,1 but also dopaminergic input ...

The role of this receptor subtype in addiction disorders recently was studied in humans. The report demonstrated that alcohol dependence in humans, like in rodent models, is associated with increased levels of ventral striatal 5-HT1B receptors (Hu et al. 2010). Additional research is necessary to understand the complex function of the 5-HT system. However, these findings suggest possible novel targets for the treatment of stress-related disorders and, most important, addiction disorders.

Dopamine

Dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain project to the nucleus accumbens and other limbic areas to form the mesolimbic dopamine system, the most studied reward circuit. Dopamine neurons are activated in response to reward or the expectation of reward, and generally are inhibited by aversive stimuli. Dopamine signaling is central to the onset of addiction, as well as to the transition to dependence in interaction with other neurotransmitter systems (Ross and Peselow 2009). Drugs of addiction trigger large but brief increases in extracellular dopamine in the nucleus accumbens. Over time, chronic drug use downregulates dopamine receptors and dopamine release, leading to decreased sensitivity to natural rewards, such as food and sex, and leading also to further drug use (Volkow et al 2010).

Although findings from animal studies suggest that early-life stress can lead to long-lasting changes in gene expression in the mesolimbic dopamine pathway, ultimately increasing vulnerability to addictive disorders, not all individuals with a history of childhood abuse develop addictive or other disorders, thereby stressing the role of protective factors such as genetic variants conferring resilience (Enoch 2010).

Findings from several studies suggest that higher dopamine D2 receptor availability in the striatum might promote resilience to alcohol use disorders. In a study of unaffected members of alcoholic families, higher striatal dopamine D2 receptor availability was associated with higher positive emotionality, discussed above as a protective factor against alcohol use disorders (Volkow et al 2006). Other studies found that higher striatal dopamine D2 receptor availability was associated with resistance to the reinforcing effects of stimulants in healthy volunteers (Volkow et al. 1999, 2002) and in rats (Thanos et al. 2008).

NPY

NPY, a 36–amino acid peptide, is widely distributed in the brain. NPY has anxiety-reducing properties in rodents and is thought to enhance resilience to stress in humans (Feder et al. 2009; Morgan et al. 2000). Evidence from animal and human studies suggests that NPY has a key role in regulating alcohol intake, dependence, and withdrawal. Mice genetically modified to overexpress NPY consume less alcohol (Thiele et al. 1998), and administration of NPY into the cerebral ventricles of the brain (i.e., intracerebroventricular infusion) reduces alcohol consumption in alcohol-preferring rats (Thorsell 2007). Infusion of NPY into the central nucleus of the amygdala has been shown to normalize both anxiety behaviors and alcohol intake, suggesting that NPY might work by modulating anxiety responses (Zhang et al. 2010). In rhesus macaques exposed to early life stress, and in human studies, certain NPY gene polymorphisms are associated with differential susceptibility to alcohol or cocaine dependence (Koehnke et al. 2002; Lindell et al. 2010; Mottagui-Tabar et al. 2005; Wetherill et al. 2008).

Endocannabinoids

An emerging body of evidence suggests an important role for the endogenous cannabinoid (eCB) system and specifically the CB1 receptor in alcohol-related behaviors (for review, see Basavarajappa 2007). To date, however, only peripheral measures of eCB function have been collected in living humans with alcohol dependence (AD) (Mangieri et al. 2009), and no human in vivo data on the potentially critical role of the brain CB1 receptor in AD have been collected yet. At a neurobiological level, studies show impairments in decision making in alcohol-dependent patients (Dom et al. 2006), which is associated with altered functions in a cortico-limbic-striatal circuit, including the amygdala, hippocampus, anterior cingulate cortex, insula, and the ventral striatum. Three sets of factors are thought to be responsible for high alcohol relapse rates. First, individual differences in the positive, reinforcing properties of alcohol are known to increase risk of alcoholism and possibly alcohol relapse (Schuckit and Smith 1996). Second, stimuli previously associated with alcohol use and its physiological and subjective effects become paired with alcohol and are thought to serve as “conditioned cues” that can increase alcohol craving and subsequent alcohol use (O’Brien et al. 1998). Finally, stress has been found to increase the risk of alcohol relapse (Brown et al. 1990; Miller et al. 1996; Sinha 2001). All three factors can be linked to the eCB system and its attending CB1 receptor and increasing evidence derived from animal studies suggests a role of the eCB system in alcohol-related behaviors (Vinod and Hungund 2006).

Such research suggests that upregulation of CB1 receptor–mediated G-protein signaling in a brain circuit that mediates AD susceptibility (involving the amygdala, hippocampus, ventromedial prefrontal cortex, insula, and ventral striatum) (Sullivan and Pfefferbaum 2005) might contribute to the increased alcohol consumption in patients with chronic AD. For example, CB1 inactivation (Hungund et al. 2003; Naassila et al. 2004; Poncelet et al. 2003; Thanos et al. 2005) and pharmacological manipulation of CB1 receptor function (Femenia et al. 2010; Maccioni et al.; Maccioni et al. 2008; Malinen and Hyytia 2008) result in reduced voluntary alcohol intake. In addition, administration of an agent that binds to the CB1 receptor (i.e., a CB1 receptor agonist) (Colombo et al. 2002; Gallate et al. 1999; Vinod et al. 2008b) enhances alcohol consumption.

In contrast, acute, short-term alcohol intoxication is associated with elevated eCB levels (Basavarajappa et al. 2006; Blednov et al. 2007; Vinod et al. 2008a), reduced activity of the enzyme fatty acid amide hydrolase (FAAH), and reduced CB1 receptor–mediated G-protein signaling (Vinod et al. 2011). This mediates the activation of the mesolimbic dopaminergic system (Cheer et al. 2007; Hungund et al. 2003), which has been extensively studied in alcohol dependence. Evidence suggests a functional interaction between these systems, which might be associated with the reinforcing effects of alcohol and therefore may be an important mechanism in the etiology of alcohol dependence. Findings in animal studies recently have stimulated interest in the therapeutic potential of enhancing eCB signaling, with research in humans having just begun (Hill et al. 2009). However, an accumulating body of evidence suggests that the eCB system, and in particular its attending CB1 receptor, provides novel leads for treatment development in alcohol dependence (Bailey and Neumeister 2011).

Behavioral Interventions to Enhance Resilience

To date, most studies on resilience have been conducted in clinical populations with people exposed to traumatic life events as a prototype of stress-related disorders. However, these studies also can inform the development and implementation of behavioral interventions to address alcohol dependence. This is a critical application because the ultimate goal of research attempting to delineate a range of psychological, neurochemical, and brain circuitry mechanisms underlying resilience is the development of strategies and interventions aimed at enhancing resilience in the face of stress, which is of particular relevance for people struggling with alcohol dependence. As related to alcohol dependence, improving resilience would influence cognitive and emotional control in the face of stress, resulting in the ability to weather cravings without using alcohol, mindfulness to be aware of impulsive behavior and potentially avoid impulsive behaviors associated with alcohol use, and the development of prosocial behavior and interpersonal relations that could serve to support the individual in the face of stress and prevent alcohol use. Several cognitive and behavioral interventions have been developed in an effort to develop these capacities. These interventions, which include various forms of cognitive and behavioral psychotherapies (Butler et al. 2006; Marlatt 2001), mindfulness-based stress reduction (e.g., Astin 1997; Shapiro et al. 1998; Teasdale et al. 2000) and other therapeutic approaches, aim to help prevent the onset or minimize the extent of alcohol use behaviors. In addition, therapeutic approaches based on positive psychology might also help promote psychological resilience (e.g., Seligman and Csikszentmihalyi 2000) and are currently being evaluated for their effectiveness in addressing alcohol dependence.

Taken together, interventions aimed at enhancing resilience to stress that focus on developing cognitive reappraisal skills, fostering mindfulness, and facilitating social interaction that results in enhanced social support could be particularly effective in helping people cope with stress and preventing the onset of alcohol use problems or relapse. Indeed, cognitive–behavioral models of addiction and relapse treatment such as those provided by Marlatt and colleagues (e.g., Marlatt 2001) highlight the role of experiencing negative affect as a primary trigger for using alcohol and relapsing. Mindfulness skills can be particularly useful in helping an individual cope with negative affect in the moment without resorting to the use of substances. Moreover, the attributions that individuals make upon relapsing (whether the attribution for use is internal and stable: “I just can’t handle stress and I’m bound to keep using”—versus external and unstable: “This was really stressful and difficult to deal with, and I decided to take the easy route this time”) can influence whether the relapse develops into a full-blown relapse or remains an isolated event. Cognitive reappraisal of these situations and the attributions that individuals make of their alcohol use can thus be of great importance in developing resilience in the treatment of alcohol use disorders.

Conclusions and Future Directions

Despite extensive research and knowledge regarding their serious adverse consequences, addiction disorders continue to contribute to the top preventable causes of death and morbidity in the United States (Centers for Disease Control and Prevention 2003). The mechanisms underlying the persistent and compulsive engagement in these behaviors remain poorly understood. Based on previous evidence, researchers have hypothesized that the chronic nature of addiction disorders is rooted in the neurotoxic effects of stress on the brain. These effects undermine the neuroplasticity within networks required for the recovery process to take place. As a result, mechanisms of resilience are crucial to the understanding of neuroadaptive potential and its behavioral consequences. This is an important topic of current research, which stands at a unique crossroad in the study of addiction disorders. The explosion in the field of molecular and cellular neuroscience calls for interdisciplinary, collaborative team-based approaches. A greater understanding of the neurobiology of stress and resilience, as well as its implications on the neurobiology of addictions, is crucial to the prevention of such disorders and to the development of evidence-based treatment strategies.

Footnotes

Financial Disclosures

This paper was supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) through the following awards: R21 AA–018329, RL1 AA–017540, and RL1 AA–017540–S1.

References

  • Ahmad S, Feder A, Lee EJ, et al. Earthquake impact in a remote South Asian population: Psychosocial factors and posttraumatic symptoms. Journal of Traumatic Stress. 2010;23(3):408–412. [PubMed]
  • Alim TN, Feder A, Graves RE, et al. Trauma, resilience, and recovery in a high-risk African-American population. American Journal of Psychiatry. 2008;165(12):1566–1575. [PubMed]
  • Astin JA. Stress reduction through mindfulness meditation: Effects on psychological symptomatology, sense of control, and spiritual experiences. Psychotherapy and Psychosomatics. 1997;66(2):97–106. [PubMed]
  • Bailey CR, Neumeister A. Cb1 receptor-mediated signaling emerges as a novel lead to evidence-based treatment development for stress-related psychopathology. Neuroscience Letters. 2011;502(1):1–4. [PubMed]
  • Barr CS, Schwandt ML, Newman TK, Higley JD. The use of adolescent nonhuman primates to model human alcohol intake: Neurobiological, genetic, and psychological variables. Annals of the New York Academy of Sciences. 2004;1021:221–233. [PubMed]
  • Basavarajappa BS. The endocannabinoid signaling system: A potential target for next-generation therapeutics for alcoholism. Mini Reviews in Medicinal Chemistry. 2007;7(8):769–779. [PMC free article] [PubMed]
  • Basavarajappa BS, Yalamanchili R, Cravatt BF, et al. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology. 2006;50(7):834–844. [PubMed]
  • Baumeister RF. Ego depletion and self-regulation failure: A resource model of self-control. Alcoholism: Clinical and Experimental Research. 2003;27(2):281–284. [PubMed]
  • Baumeister RF, Heatherton TF, Tice DM. Losing Control: How and Why People Fail at Self-Regulation. San Diego, CA: Academic Press; 1994.
  • Beauregard M. Mind does really matter: Evidence from neuroimaging studies of emotional self-regulation, psychotherapy, and placebo effect. Progress in Neurobiology. 2007;81(4):218–236. [PubMed]
  • Blednov YA, Cravatt BF, Boehm SL, 2nd, et al. Role of endocannabinoids in alcohol consumption and intoxication: Studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology. 2007;32(7):1570–1582. [PubMed]
  • Blomeyer D, Treutlein J, Esser G, et al. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biological Psychiatry. 2008;63(2):146–151. [PubMed]
  • Bonanno GA. Loss, trauma, and human resilience: Have we underestimated the human capacity to thrive after extremely aversive events? American Psychologist. 2004;59(1):20–28. [PubMed]
  • Brady KT, Sinha R. Co-occurring mental and substance use disorders: The neurobiological effects of chronic stress. American Journal of Psychiatry. 2005;162(8):1483–1493. [PubMed]
  • Brown SA, Vik PW, McQuaid JR, et al. Severity of psychosocial stress and outcome of alcoholism treatment. Journal of Abnormal Psychology. 1990;99(4):344–348. [PubMed]
  • Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clinical Psychology Review. 2006;26(1):17–31. [PubMed]
  • Campolongo P, Roozendaal B, Trezza V, et al. Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(12):4888–4893. [PubMed]
  • Carver CS. You want to measure coping but your protocol’s too long: Consider the brief COPE. International Journal of Behavioral Medicine. 1997;4(1):92–100. [PubMed]
  • Celerier A, Ognard R, Decorte L, Beracochea D. Deficits of spatial and non-spatial memory and of auditory fear conditioning following anterior thalamic lesions in mice: Comparison with chronic alcohol consumption. European Journal of Neuroscience. 2000;12:2575–2584. [PubMed]
  • Centers for Disease Control and Prevention, National Center for Health Statistics Health, United States, 2003 with Chartbook on Trends in the Health of Americans. Washington, DC: Department of Health and Human Services; 2003. [ DHHS PHS No. 2003–1232].
  • Charney DS. Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. American Journal of Psychiatry. 2004;161(2):195–216. [PubMed]
  • Charuvastra A, Cloitre M. Social bonds and post-traumatic stress disorder. Annual Review of Psychology. 2008;59:301–328. [PMC free article] [PubMed]
  • Cheer JF, Wassum KM, Sombers LA, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. Journal of Neuroscience. 2007;27(4):791–795. [PubMed]
  • Cicchetti D, Blender JA. A multiple-levels-of-analysis perspective on resilience: Implications for the developing brain, neural plasticity, and preventive interventions. Annals of the New York Academy of Sciences. 2006;1094:248–258. [PubMed]
  • Clark MS, Neumaier JF. The 5-HT1B receptor: Behavioral implications. Psychopharmacology Bulletin. 2001;35(4):170–185. [PubMed]
  • Colombo G, Serra S, Brunetti G, et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berlin) 2002;159(2):181–187. [PubMed]
  • Cooper ML, Russell M, Skinner JB, et al. Stress and alcohol use: Moderating effects of gender, coping, and alcohol expectancies. Journal of Abnormal Psychology. 1992;101(1):139–152. [PubMed]
  • Dai X, Thavundayil J, Santella S, Gianoulakis C. Response of the HPA-axis to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Psychoneuroendocrinology. 2007;32(3):293–305. [PubMed]
  • Dallman MF, Pecoraro NC, la Fleur SE. Chronic stress and comfort foods: Self-medication and abdominal obesity. Brain, Behavior, and Immunity. 2005;19(4):275–280. [PubMed]
  • de Kloet ER, Derijk RH, Meijer OC. Therapy Insight: Is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nature Clinical Practice Endocrinology & Metabolism. 2007;3(2):168–179. [PubMed]
  • de Kloet ER, Joels M, Holsboer F. Stress and the brain: From adaptation to disease. Nature Reviews Neuroscience. 2005;6(6):463–475. [PubMed]
  • Delgado MR, Olsson A, Phelps EA. Extending animal models of fear conditioning to humans. Biological Psychology. 2006;73(1):39–48. [PubMed]
  • Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949. [PubMed]
  • Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372(6507):686–691. [PubMed]
  • Ding YS, Lin KS, Logan J, et al. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. Journal of Neurochemistry. 2005;94(2):337–351. [PubMed]
  • Dom G, De Wilde B, Hulstijn W, et al. Decision-making deficits in alcohol-dependent patients with and without comorbid personality disorder. Alcoholism: Clinical and Experimental Research. 2006;30(10):1670–1677. [PubMed]
  • Drabant EM, Hariri AR, Meyer-Lindenberg A, et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Archives of General Psychiatry. 2006;63(12):1396–1406. [PubMed]
  • Drabant EM, McRae K, Manuck SB, et al. Individual differences in typical reappraisal use predict amygdala and prefrontal responses. Biological Psychiatry. 2009;65(5):367–373. [PMC free article] [PubMed]
  • Enoch MA. The role of early life stress as a predictor for alcohol and drug dependence. Psychopharmacology. 2011;214(1):17–31. [PMC free article] [PubMed]
  • Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nature Reviews Neuroscience. 2009;10(6):446–457. [PMC free article] [PubMed]
  • Femenia T, Garcia-Gutierrez MS, Manzanares J. CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats. Alcoholism: Clinical and Experimental Research. 2010;34(1):131–141. [PubMed]
  • Folkman S, Moskowitz JT. Coping: Pitfalls and promise. Annual Review of Psychology. 2004;55:745–774. [PubMed]
  • Fredrickson BL. The role of positive emotions in positive psychology: The broaden-and-build theory of positive emotions. American Psychologist. 2001;56(3):218–226. [PMC free article] [PubMed]
  • Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. European Journal of Pharmacology. 1999;370(3):233–240. [PubMed]
  • Gianoulakis C, Dai X, Thavundayil J, Brown T. Levels and circadian rhythmicity of plasma ACTH, cortisol, and beta-endorphin as a function of family history of alcoholism. Psychopharmacology (Berlin) 2005;181(3):437–444. [PubMed]
  • Hakamata Y, Lissek S, Bar-Haim Y, et al. Attention bias modification treatment: A meta-analysis toward the establishment of novel treatment for anxiety. Biological Psychiatry. 2010;68(11):982–990. [PMC free article] [PubMed]
  • Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Archives of General Psychiatry. 2005;62(2):146–152. [PubMed]
  • Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biological Psychiatry. 2001;49(12):1023–1039. [PubMed]
  • Herkenham M, Groen BG, Lynn AB, et al. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Research. 1991;552(2):301–310. [PubMed]
  • Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. Journal of Neuroscience. 1991;11(2):563–583. [PubMed]
  • Hill MN, Hillard CJ, Bambico FR, et al. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends in Pharmacological Sciences. 2009;30(9):484–493. [PubMed]
  • Hill MN, McEwen BS. Endocannabinoids: The silent partner of glucocorticoids in the synapse. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(12):4579–4580. [PubMed]
  • Hoebel BG, Avena NM, Rada P. Accumbens dopamine-acetylcholine balance in approach and avoidance. Current Opinion in Pharmacology. 2007;7(6):617–627. [PMC free article] [PubMed]
  • Hu J, Henry S, Gallezot JD, et al. Serotonin 1B receptor imaging in alcohol dependence. Biological Psychiatry. 2010;67(9):800–803. [PMC free article] [PubMed]
  • Hungund BL, Szakall I, Adam A, et al. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. Journal of Neurochemistry. 2003;84(4):698–704. [PubMed]
  • Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: The role of reward-related learning and memory. Annual Review of Neuroscience. 2006;29:565–598. [PubMed]
  • Johnstone T, van Reekum CM, Urry HL, et al. Failure to regulate: Counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. Journal of Neuroscience. 2007;27(33):8877–8884. [PubMed]
  • Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. American Journal of Psychiatry. 2005;162(8):1403–1413. [PubMed]
  • Kirby LB, Zeeb FD, Winstanley CA. Contributions of serotonin in addiction vulnerability. Neuropharmacology. 2011;61(3):421–432. [PMC free article] [PubMed]
  • Kober H, Mende-Siedlecki P, Kross EF, et al. Prefrontal-striatal pathway underlies cognitive regulation of craving. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(33):14811–14816. [PubMed]
  • Koehnke MD, Schick S, Lutz U, et al. Severity of alcohol withdrawal symptoms and the T1128C polymorphism of the neuropeptide Y gene. Journal of Neural Transmission. 2002;109(11):1423–1429. [PubMed]
  • Koob GF. Alcoholism: Allostasis and beyond. Alcoholism: Clinical and Experimental Research. 2003;27(2):232–243. [PubMed]
  • Koob GF. Dynamics of neuronal circuits in addiction: Reward, antireward, and emotional memory. Pharmacopsychiatry. 2009;42(Suppl. 1):S32–S41. [PMC free article] [PubMed]
  • Koob GF, Ahmed SH, Boutrel B, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neuroscience and Biobehavioral Reviews. 2004;27(8):739–749. [PubMed]
  • Koob GF, Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science. 1997;278(5335):52–58. [PubMed]
  • Koob GF, Le Moal M. Review: Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2008;363(1507):3113–3123. [PMC free article] [PubMed]
  • Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Research. 2009;1293:13–23. [PMC free article] [PubMed]
  • Lazarus RS, Fokman S. Stress, Appraisal, and Coping. New York: Springer; 1984.
  • Le AD, Harding S, Juzytsch W, et al. Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berlin) 2005;179(2):366–373. [PubMed]
  • Lee V, Cohen SR, Edgar L, et al. Clarifying “meaning” in the context of cancer research: A systematic literature review. Palliative & Supportive Care. 2004;2(3):291–303. [PubMed]
  • Lindell SG, Schwandt ML, Sun H, et al. Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Archives of General Psychiatry. 2010;67(4):423–431. [PMC free article] [PubMed]
  • Maccioni P, Pes D, Carai MA, et al. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. Behavioural Pharmacology. 2008;19(3):197–209. [PubMed]
  • Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handbook of Experimental Pharmacology. 2005;168:299–325. [PubMed]
  • MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(3):1387–1392. [PubMed]
  • Malinen H, Hyytia P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcoholism: Clinical and Experimental Research. 2008;32(11):1976–1983. [PubMed]
  • Mangieri RA, Hong KI, Piomelli D, Sinha R. An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berlin) 2009;205(1):63–72. [PMC free article] [PubMed]
  • Marinelli PW, Bai L, Quirion R, Gianoulakis C. A microdialysis profile of Met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcoholism: Clinical and Experimental Research. 2005;29(10):1821–1828. [PubMed]
  • Marinelli PW, Funk D, Juzytsch W, et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berlin) 2007;195(3):345–355. [PubMed]
  • Marlatt GA. Should abstinence be the goal for alcohol treatment? Negative viewpoint. American Journal on Addictions. 2001;10(4):291–293. [PubMed]
  • Masten AS. Ordinary magic: Resilience processes in development. American Psychologist. 2001;56(3):227–238. [PubMed]
  • Masten AS, Coatsworth JD. The development of competence in favorable and unfavorable environments: Lessons from research on successful children. American Psychologist. 1998;53(2):205–220. [PubMed]
  • Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. Journal of Comparative Neurology. 1993;327(4):535–550. [PubMed]
  • McCool BA, Christian DT, Diaz MR, Lack AK. Glutamate plasticity in the drunken amygdala: The making of an anxious synapse. International Review of Neurobiology. 2010;91:205–233. [PMC free article] [PubMed]
  • McEwen BS. Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology. 2000;22(2):108–124. [PubMed]
  • McEwen BS. Mood disorders and allostatic load. Biological Psychiatry. 2003;54(3):200–207. [PubMed]
  • Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50(1):83–90. [PubMed]
  • Milad MR, Quinn BT, Pitman RK, et al. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(30):10706–10711. [PubMed]
  • Miller WR, Westerberg VS, Harris RJ, Tonigan JS. What predicts relapse? Prospective testing of antecedent models. Addiction. 1996;91(Suppl):S155–S172. [PubMed]
  • Miner LH, Jedema HP, Moore FW, et al. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. Journal of Neuroscience. 2006;26(5):1571–1578. [PubMed]
  • Morgan CA, 3rd, Wang S, Southwick SM, et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biological Psychiatry. 2000;47(10):902–909. [PubMed]
  • Mottagui-Tabar S, Prince JA, Wahlestedt C, et al. A novel single nucleotide polymorphism of the neuropeptide Y (NPY) gene associated with alcohol dependence. Alcoholism: Clinical and Experimental Research. 2005;29(5):702–707. [PubMed]
  • Naassila M, Pierrefiche O, Ledent C, Daoust M. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology. 2004;46(2):243–253. [PubMed]
  • Neumeister A, Charney DS, Belfer I, et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenetics and Genomics. 2005;15(3):143–149. [PubMed]
  • O’Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: Can they explain compulsion? Journal of Psychopharmacology. 1998;12(1):15–22. [PubMed]
  • O’Donnell T, Hegadoren KM, Coupland NC. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiology. 2004;50(4):273–283. [PubMed]
  • Ong AD, Bergeman CS, Bisconti TL, Wallace KA. Psychological resilience, positive emotions, and successful adaptation to stress in later life. Journal of Personality and Social Psychology. 2006;91(4):730–749. [PubMed]
  • Pargament KI, Smith BW, Koenig HG, Perez L. Patterns of positive and negative religious coping with major life stressors. Journal for the Scientific Study of Religion. 37:710–724.
  • Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nature Neuroscience. 2005;8(6):828–834. [PubMed]
  • Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neuroscience Letters. 2003;343(3):216–218. [PubMed]
  • Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research—past, present, and future. Biological Psychiatry. 2006;60(4):376–382. [PubMed]
  • Richardson K, Baillie A, Reid S, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008;103(6):953–959. [PubMed]
  • Robles TF, Kiecolt-Glaser JK. The physiology of marriage: Pathways to health. Physiology & Behavior. 2003;79(3):409–416. [PubMed]
  • Roffman JL, Marci CD, Glick DM, et al. Neuroimaging and the functional neuroanatomy of psychotherapy. Psychological Medicine. 35(10):1385–1398. [PubMed]
  • Ross S, Peselow E. The neurobiology of addictive disorders. Clinical Neuropharmacology. 2009;32(5):269–276. [PubMed]
  • Rutter M. Resilience in the face of adversity: Protective factors and resistance to psychiatric disorder. British Journal of Psychiatry. 1985;147:598–611. [PubMed]
  • Sallinen J, Haapalinna A, MacDonald E, et al. Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Molecular Psychiatry. 1999;4(5):443–452. [PubMed]
  • Sari Y. Serotonin1B receptors: From protein to physiological function and behavior. Neuroscience and Biobehavioral Reviews. 2004;28(6):565–582. [PubMed]
  • Schmid B, Blomeyer D, Treutlein J, et al. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. International Journal of Neuropsychopharmacology. 2010;13(6):703–714. [PubMed]
  • Schuckit MA, Smith TL. An 8-year follow-up of 450 sons of alcoholic and control subjects. Archives of General Psychiatry. 1996;53(3):202–210. [PubMed]
  • Seligman ME, Csikszentmihalyi M. Positive psychology: An introduction. American Psychologist. 2000;55(1):5–14. [PubMed]
  • Selye H. The Stress of Life. New York: McGraw-Hill; 1976.
  • Shapiro SL, Schwartz GE, Bonner G. Effects of mindfulness-based stress reduction on medical and pre-medical students. Journal of Behavioral Medicine. 1998;21(6):581–599. [PubMed]
  • Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berlin) 2001;158(4):343–359. [PubMed]
  • Sinha R, Fox HC, Hong KI, et al. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Archives of General Psychiatry. 2011;68(9):942–952. [PMC free article] [PubMed]
  • Small KM, Forbes SL, Rahman FF, et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. Journal of Biological Chemistry. 2000;275(30):23059–23064. [PubMed]
  • Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annual Review of Clinical Psychology. 2005;1:255–291. [PubMed]
  • Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388(6644):773–778. [PubMed]
  • Stephens DN, Ripley TL, Borlikova G, et al. Repeated ethanol exposure and withdrawal impairs human fear conditioning and depresses long-term potentiation in rat amygdala and hippocampus. Biological Psychiatry. 2005;58(5):392–400. [PubMed]
  • Sterling P, Eyer J. Allostasis: A New Paradigm to Explain Arousal Pathology. New York: John Wiley & Sons; 1988.
  • Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications. 1995;215(1):89–97. [PubMed]
  • Sullivan EV, Pfefferbaum A. Neurocircuitry in alcoholism: A substrate of disruption and repair. Psychopharmacology (Berlin) 2005;180(4):583–594. [PubMed]
  • Teasdale JD, Segal ZV, Williams JM, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology. 2000;68(4):615–623. [PubMed]
  • Thanos PK, Michaelides M, Umegaki H, Volkow ND. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse. 2008;62(7):481–486. [PMC free article] [PubMed]
  • Thiele TE, Marsh DJ, Ste Marie L, et al. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature. 1998;396(6709):366–369. [PubMed]
  • Thorsell A. Neuropeptide Y (NPY) in alcohol intake and dependence. Peptides. 2007;28(2):480–483. [PubMed]
  • Tugade MM, Fredrickson BL. Resilient individuals use positive emotions to bounce back from negative emotional experiences. Journal of Personality and Social Psychology. 2004;86(2):320–333. [PMC free article] [PubMed]
  • Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–332. [PubMed]
  • Veenstra MY, Lemmens PH, Friesema IH, et al. Coping style mediates impact of stress on alcohol use: A prospective population-based study. Addiction. 2007;102(12):1890–1898. [PubMed]
  • Vinod KY, Hungund BL. Cannabinoid-1 receptor: A novel target for the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets. 2006;10(2):203–210. [PubMed]
  • Vinod KY, Sanguino E, Yalamanchili R, et al. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. Journal of Neurochemistry. 2008b;104(1):233–243. [PubMed]
  • Vinod KY, Yalamanchili R, Thanos PK, et al. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse. 2008a;62(8):574–581. [PMC free article] [PubMed]
  • Vinod KY, Yalamanchili R, Xie S, et al. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochemistry International. 2006;49(6):619–625. [PubMed]
  • Vinod KY, Kassir SA, Hungund BL, et al. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. Journal of Psychiatric Research. 2010;44(9):591–597. [PMC free article] [PubMed]
  • Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: Results from imaging studies. Behavioural Pharmacology. 2002;13(5–6):355–366. [PubMed]
  • Volkow ND, Wang GJ, Begleiter H, et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: Possible protective factors. Archives of General Psychiatry. 2006;63(9):999–1008. [PubMed]
  • Volkow ND, Wang GJ, Fowler JS, et al. Addiction: Decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit. BioEssays. 2010;32(9):748–755. [PMC free article] [PubMed]
  • Volkow P, Tellez O, Allende S, Vazquez C. Drug abuse through a long-indwelling catheter cared for by an intravenous team. American Journal of Infection Control. 1999;27(5):459. [PubMed]
  • Vythilingam M, Nelson EE, Scaramozza M, et al. Reward circuitry in resilience to severe trauma: An fMRI investigation of resilient special forces soldiers. Psychiatry Research. 2009;172(1):75–77. [PMC free article] [PubMed]
  • Wager TD, Davidson ML, Hughes BL, et al. Prefrontal-subcortical pathways mediating successful emotion regulation. Neuron. 2008;59(6):1037–1050. [PMC free article] [PubMed]
  • Wetherill L, Schuckit MA, Hesselbrock V, et al. Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. Alcoholism: Clinical and Experimental Research. 2008;32(12):2031–2040. [PMC free article] [PubMed]
  • Wills TA, Sandy JM, Yaeger AM, et al. Coping dimensions, life stress, and adolescent substance use: A latent growth analysis. Journal of Abnormal Psychology. 110(2):309–323. [PubMed]
  • Yacubian J, Sommer T, Schroeder K, et al. Gene–gene interaction associated with neural reward sensitivity. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(19):8125–8130. [PubMed]
  • Yehuda R, LeDoux J. Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron. 2007;56(1):19–32. [PubMed]
  • Zhang H, Sakharkar AJ, Shi G, et al. Neuropeptide Y signaling in the central nucleus of amygdala regulates alcohol-drinking and anxiety-like behaviors of alcohol-preferring rats. Alcoholism: Clinical and Experimental Research. 2010;34(3):451–461. [PMC free article] [PubMed]

Articles from Alcohol Research : Current Reviews are provided here courtesy of National Institute on Alcohol Abuse and Alcoholism